Critical Analysis: Nkarta (NASDAQ:NKTX) versus Contineum Therapeutics (NASDAQ:CTNM)

Nkarta (NASDAQ:NKTX – Get Free Report) and Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Nkarta and Contineum Therapeutics’ net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Nkarta and Contineum Therapeutics, as reported by MarketBeat.

Nkarta currently has a consensus price target of $10.75, indicating a potential upside of 275.87%. Contineum Therapeutics has a consensus price target of $20.00, indicating a potential upside of 67.50%. Given Nkarta’s stronger consensus rating and higher probable upside, analysts plainly believe Nkarta is more favorable than Contineum Therapeutics.

Institutional & Insider Ownership

80.5% of Nkarta shares are owned by institutional investors. 9.8% of Nkarta shares are owned by insiders. Comparatively, 7.9% of Contineum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Nkarta and Contineum Therapeutics”s top-line revenue, earnings per share and valuation.

Contineum Therapeutics has higher revenue and earnings than Nkarta. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Nkarta has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Contineum Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.

Summary

Nkarta beats Contineum Therapeutics on 9 of the 12 factors compared between the two stocks.

About Nkarta

(Get Free Report)

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

About Contineum Therapeutics

(Get Free Report)

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.